nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Vomiting—Ifosfamide—testicular cancer	0.000904	0.000904	CcSEcCtD
Gadoversetamide—Hypersensitivity—Cisplatin—testicular cancer	0.000903	0.000903	CcSEcCtD
Gadoversetamide—Rash—Ifosfamide—testicular cancer	0.000897	0.000897	CcSEcCtD
Gadoversetamide—Dermatitis—Ifosfamide—testicular cancer	0.000896	0.000896	CcSEcCtD
Gadoversetamide—Erythema multiforme—Methotrexate—testicular cancer	0.000895	0.000895	CcSEcCtD
Gadoversetamide—Urticaria—Etoposide—testicular cancer	0.000892	0.000892	CcSEcCtD
Gadoversetamide—Haemoglobin—Epirubicin—testicular cancer	0.000891	0.000891	CcSEcCtD
Gadoversetamide—Rhinitis—Epirubicin—testicular cancer	0.000888	0.000888	CcSEcCtD
Gadoversetamide—Abdominal pain—Etoposide—testicular cancer	0.000888	0.000888	CcSEcCtD
Gadoversetamide—Body temperature increased—Etoposide—testicular cancer	0.000888	0.000888	CcSEcCtD
Gadoversetamide—Conjunctivitis—Doxorubicin—testicular cancer	0.000888	0.000888	CcSEcCtD
Gadoversetamide—Urinary tract infection—Doxorubicin—testicular cancer	0.000888	0.000888	CcSEcCtD
Gadoversetamide—Haemorrhage—Epirubicin—testicular cancer	0.000886	0.000886	CcSEcCtD
Gadoversetamide—Eye disorder—Methotrexate—testicular cancer	0.000885	0.000885	CcSEcCtD
Gadoversetamide—Tinnitus—Methotrexate—testicular cancer	0.000883	0.000883	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Epirubicin—testicular cancer	0.000882	0.000882	CcSEcCtD
Gadoversetamide—Asthenia—Cisplatin—testicular cancer	0.00088	0.00088	CcSEcCtD
Gadoversetamide—Pharyngitis—Epirubicin—testicular cancer	0.00088	0.00088	CcSEcCtD
Gadoversetamide—Cardiac disorder—Methotrexate—testicular cancer	0.000879	0.000879	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Epirubicin—testicular cancer	0.000875	0.000875	CcSEcCtD
Gadoversetamide—Oedema peripheral—Epirubicin—testicular cancer	0.000873	0.000873	CcSEcCtD
Gadoversetamide—Haematuria—Doxorubicin—testicular cancer	0.000871	0.000871	CcSEcCtD
Gadoversetamide—Urethral disorder—Epirubicin—testicular cancer	0.000869	0.000869	CcSEcCtD
Gadoversetamide—Epistaxis—Doxorubicin—testicular cancer	0.000862	0.000862	CcSEcCtD
Gadoversetamide—Angiopathy—Methotrexate—testicular cancer	0.000859	0.000859	CcSEcCtD
Gadoversetamide—Sinusitis—Doxorubicin—testicular cancer	0.000857	0.000857	CcSEcCtD
Gadoversetamide—Immune system disorder—Methotrexate—testicular cancer	0.000855	0.000855	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Methotrexate—testicular cancer	0.000853	0.000853	CcSEcCtD
Gadoversetamide—Chills—Methotrexate—testicular cancer	0.00085	0.00085	CcSEcCtD
Gadoversetamide—Nausea—Ifosfamide—testicular cancer	0.000845	0.000845	CcSEcCtD
Gadoversetamide—Diarrhoea—Cisplatin—testicular cancer	0.000839	0.000839	CcSEcCtD
Gadoversetamide—Erythema multiforme—Epirubicin—testicular cancer	0.000838	0.000838	CcSEcCtD
Gadoversetamide—Mental disorder—Methotrexate—testicular cancer	0.00083	0.00083	CcSEcCtD
Gadoversetamide—Eye disorder—Epirubicin—testicular cancer	0.000828	0.000828	CcSEcCtD
Gadoversetamide—Hypersensitivity—Etoposide—testicular cancer	0.000827	0.000827	CcSEcCtD
Gadoversetamide—Tinnitus—Epirubicin—testicular cancer	0.000826	0.000826	CcSEcCtD
Gadoversetamide—Erythema—Methotrexate—testicular cancer	0.000824	0.000824	CcSEcCtD
Gadoversetamide—Malnutrition—Methotrexate—testicular cancer	0.000824	0.000824	CcSEcCtD
Gadoversetamide—Haemoglobin—Doxorubicin—testicular cancer	0.000824	0.000824	CcSEcCtD
Gadoversetamide—Cardiac disorder—Epirubicin—testicular cancer	0.000822	0.000822	CcSEcCtD
Gadoversetamide—Flushing—Epirubicin—testicular cancer	0.000822	0.000822	CcSEcCtD
Gadoversetamide—Rhinitis—Doxorubicin—testicular cancer	0.000822	0.000822	CcSEcCtD
Gadoversetamide—Haemorrhage—Doxorubicin—testicular cancer	0.00082	0.00082	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Doxorubicin—testicular cancer	0.000816	0.000816	CcSEcCtD
Gadoversetamide—Pharyngitis—Doxorubicin—testicular cancer	0.000814	0.000814	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Doxorubicin—testicular cancer	0.00081	0.00081	CcSEcCtD
Gadoversetamide—Oedema peripheral—Doxorubicin—testicular cancer	0.000808	0.000808	CcSEcCtD
Gadoversetamide—Dysgeusia—Methotrexate—testicular cancer	0.000807	0.000807	CcSEcCtD
Gadoversetamide—Asthenia—Etoposide—testicular cancer	0.000806	0.000806	CcSEcCtD
Gadoversetamide—Angiopathy—Epirubicin—testicular cancer	0.000804	0.000804	CcSEcCtD
Gadoversetamide—Urethral disorder—Doxorubicin—testicular cancer	0.000804	0.000804	CcSEcCtD
Gadoversetamide—Immune system disorder—Epirubicin—testicular cancer	0.0008	0.0008	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Epirubicin—testicular cancer	0.000799	0.000799	CcSEcCtD
Gadoversetamide—Back pain—Methotrexate—testicular cancer	0.000797	0.000797	CcSEcCtD
Gadoversetamide—Chills—Epirubicin—testicular cancer	0.000795	0.000795	CcSEcCtD
Gadoversetamide—Pruritus—Etoposide—testicular cancer	0.000795	0.000795	CcSEcCtD
Gadoversetamide—Arrhythmia—Epirubicin—testicular cancer	0.000792	0.000792	CcSEcCtD
Gadoversetamide—Vomiting—Cisplatin—testicular cancer	0.000779	0.000779	CcSEcCtD
Gadoversetamide—Vision blurred—Methotrexate—testicular cancer	0.000777	0.000777	CcSEcCtD
Gadoversetamide—Mental disorder—Epirubicin—testicular cancer	0.000776	0.000776	CcSEcCtD
Gadoversetamide—Erythema multiforme—Doxorubicin—testicular cancer	0.000775	0.000775	CcSEcCtD
Gadoversetamide—Rash—Cisplatin—testicular cancer	0.000773	0.000773	CcSEcCtD
Gadoversetamide—Dermatitis—Cisplatin—testicular cancer	0.000772	0.000772	CcSEcCtD
Gadoversetamide—Erythema—Epirubicin—testicular cancer	0.000771	0.000771	CcSEcCtD
Gadoversetamide—Malnutrition—Epirubicin—testicular cancer	0.000771	0.000771	CcSEcCtD
Gadoversetamide—Diarrhoea—Etoposide—testicular cancer	0.000768	0.000768	CcSEcCtD
Gadoversetamide—Eye disorder—Doxorubicin—testicular cancer	0.000766	0.000766	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Methotrexate—testicular cancer	0.000765	0.000765	CcSEcCtD
Gadoversetamide—Tinnitus—Doxorubicin—testicular cancer	0.000764	0.000764	CcSEcCtD
Gadoversetamide—Cardiac disorder—Doxorubicin—testicular cancer	0.000761	0.000761	CcSEcCtD
Gadoversetamide—Flushing—Doxorubicin—testicular cancer	0.000761	0.000761	CcSEcCtD
Gadoversetamide—Flatulence—Epirubicin—testicular cancer	0.00076	0.00076	CcSEcCtD
Gadoversetamide—Tension—Epirubicin—testicular cancer	0.000757	0.000757	CcSEcCtD
Gadoversetamide—Dysgeusia—Epirubicin—testicular cancer	0.000755	0.000755	CcSEcCtD
Gadoversetamide—Nervousness—Epirubicin—testicular cancer	0.000749	0.000749	CcSEcCtD
Gadoversetamide—Back pain—Epirubicin—testicular cancer	0.000746	0.000746	CcSEcCtD
Gadoversetamide—Angiopathy—Doxorubicin—testicular cancer	0.000744	0.000744	CcSEcCtD
Gadoversetamide—Malaise—Methotrexate—testicular cancer	0.000743	0.000743	CcSEcCtD
Gadoversetamide—Dizziness—Etoposide—testicular cancer	0.000743	0.000743	CcSEcCtD
Gadoversetamide—Muscle spasms—Epirubicin—testicular cancer	0.000742	0.000742	CcSEcCtD
Gadoversetamide—Immune system disorder—Doxorubicin—testicular cancer	0.000741	0.000741	CcSEcCtD
Gadoversetamide—Vertigo—Methotrexate—testicular cancer	0.000741	0.000741	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Doxorubicin—testicular cancer	0.000739	0.000739	CcSEcCtD
Gadoversetamide—Chills—Doxorubicin—testicular cancer	0.000736	0.000736	CcSEcCtD
Gadoversetamide—Arrhythmia—Doxorubicin—testicular cancer	0.000732	0.000732	CcSEcCtD
Gadoversetamide—Nausea—Cisplatin—testicular cancer	0.000728	0.000728	CcSEcCtD
Gadoversetamide—Vision blurred—Epirubicin—testicular cancer	0.000727	0.000727	CcSEcCtD
Gadoversetamide—Cough—Methotrexate—testicular cancer	0.000719	0.000719	CcSEcCtD
Gadoversetamide—Mental disorder—Doxorubicin—testicular cancer	0.000718	0.000718	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Epirubicin—testicular cancer	0.000716	0.000716	CcSEcCtD
Gadoversetamide—Convulsion—Methotrexate—testicular cancer	0.000714	0.000714	CcSEcCtD
Gadoversetamide—Vomiting—Etoposide—testicular cancer	0.000714	0.000714	CcSEcCtD
Gadoversetamide—Malnutrition—Doxorubicin—testicular cancer	0.000714	0.000714	CcSEcCtD
Gadoversetamide—Erythema—Doxorubicin—testicular cancer	0.000714	0.000714	CcSEcCtD
Gadoversetamide—Agitation—Epirubicin—testicular cancer	0.000709	0.000709	CcSEcCtD
Gadoversetamide—Rash—Etoposide—testicular cancer	0.000708	0.000708	CcSEcCtD
Gadoversetamide—Dermatitis—Etoposide—testicular cancer	0.000708	0.000708	CcSEcCtD
Gadoversetamide—Headache—Etoposide—testicular cancer	0.000704	0.000704	CcSEcCtD
Gadoversetamide—Flatulence—Doxorubicin—testicular cancer	0.000703	0.000703	CcSEcCtD
Gadoversetamide—Arthralgia—Methotrexate—testicular cancer	0.000702	0.000702	CcSEcCtD
Gadoversetamide—Myalgia—Methotrexate—testicular cancer	0.000702	0.000702	CcSEcCtD
Gadoversetamide—Chest pain—Methotrexate—testicular cancer	0.000702	0.000702	CcSEcCtD
Gadoversetamide—Tension—Doxorubicin—testicular cancer	0.0007	0.0007	CcSEcCtD
Gadoversetamide—Dysgeusia—Doxorubicin—testicular cancer	0.000699	0.000699	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000697	0.000697	CcSEcCtD
Gadoversetamide—Malaise—Epirubicin—testicular cancer	0.000696	0.000696	CcSEcCtD
Gadoversetamide—Discomfort—Methotrexate—testicular cancer	0.000693	0.000693	CcSEcCtD
Gadoversetamide—Nervousness—Doxorubicin—testicular cancer	0.000693	0.000693	CcSEcCtD
Gadoversetamide—Vertigo—Epirubicin—testicular cancer	0.000693	0.000693	CcSEcCtD
Gadoversetamide—Syncope—Epirubicin—testicular cancer	0.000692	0.000692	CcSEcCtD
Gadoversetamide—Back pain—Doxorubicin—testicular cancer	0.00069	0.00069	CcSEcCtD
Gadoversetamide—Muscle spasms—Doxorubicin—testicular cancer	0.000686	0.000686	CcSEcCtD
Gadoversetamide—Palpitations—Epirubicin—testicular cancer	0.000682	0.000682	CcSEcCtD
Gadoversetamide—Confusional state—Methotrexate—testicular cancer	0.000678	0.000678	CcSEcCtD
Gadoversetamide—Loss of consciousness—Epirubicin—testicular cancer	0.000678	0.000678	CcSEcCtD
Gadoversetamide—Cough—Epirubicin—testicular cancer	0.000673	0.000673	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Methotrexate—testicular cancer	0.000673	0.000673	CcSEcCtD
Gadoversetamide—Vision blurred—Doxorubicin—testicular cancer	0.000673	0.000673	CcSEcCtD
Gadoversetamide—Convulsion—Epirubicin—testicular cancer	0.000668	0.000668	CcSEcCtD
Gadoversetamide—Nausea—Etoposide—testicular cancer	0.000667	0.000667	CcSEcCtD
Gadoversetamide—Hypertension—Epirubicin—testicular cancer	0.000666	0.000666	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Doxorubicin—testicular cancer	0.000662	0.000662	CcSEcCtD
Gadoversetamide—Nervous system disorder—Methotrexate—testicular cancer	0.00066	0.00066	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Methotrexate—testicular cancer	0.000659	0.000659	CcSEcCtD
Gadoversetamide—Arthralgia—Epirubicin—testicular cancer	0.000657	0.000657	CcSEcCtD
Gadoversetamide—Myalgia—Epirubicin—testicular cancer	0.000657	0.000657	CcSEcCtD
Gadoversetamide—Chest pain—Epirubicin—testicular cancer	0.000657	0.000657	CcSEcCtD
Gadoversetamide—Agitation—Doxorubicin—testicular cancer	0.000656	0.000656	CcSEcCtD
Gadoversetamide—Anxiety—Epirubicin—testicular cancer	0.000654	0.000654	CcSEcCtD
Gadoversetamide—Skin disorder—Methotrexate—testicular cancer	0.000653	0.000653	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000652	0.000652	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Methotrexate—testicular cancer	0.00065	0.00065	CcSEcCtD
Gadoversetamide—Discomfort—Epirubicin—testicular cancer	0.000649	0.000649	CcSEcCtD
Gadoversetamide—Malaise—Doxorubicin—testicular cancer	0.000644	0.000644	CcSEcCtD
Gadoversetamide—Dry mouth—Epirubicin—testicular cancer	0.000642	0.000642	CcSEcCtD
Gadoversetamide—Vertigo—Doxorubicin—testicular cancer	0.000641	0.000641	CcSEcCtD
Gadoversetamide—Anorexia—Methotrexate—testicular cancer	0.000641	0.000641	CcSEcCtD
Gadoversetamide—Syncope—Doxorubicin—testicular cancer	0.00064	0.00064	CcSEcCtD
Gadoversetamide—Confusional state—Epirubicin—testicular cancer	0.000635	0.000635	CcSEcCtD
Gadoversetamide—Palpitations—Doxorubicin—testicular cancer	0.000631	0.000631	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Epirubicin—testicular cancer	0.00063	0.00063	CcSEcCtD
Gadoversetamide—Oedema—Epirubicin—testicular cancer	0.00063	0.00063	CcSEcCtD
Gadoversetamide—Hypotension—Methotrexate—testicular cancer	0.000629	0.000629	CcSEcCtD
Gadoversetamide—Loss of consciousness—Doxorubicin—testicular cancer	0.000627	0.000627	CcSEcCtD
Gadoversetamide—Cough—Doxorubicin—testicular cancer	0.000623	0.000623	CcSEcCtD
Gadoversetamide—Shock—Epirubicin—testicular cancer	0.000619	0.000619	CcSEcCtD
Gadoversetamide—Convulsion—Doxorubicin—testicular cancer	0.000618	0.000618	CcSEcCtD
Gadoversetamide—Nervous system disorder—Epirubicin—testicular cancer	0.000617	0.000617	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Epirubicin—testicular cancer	0.000616	0.000616	CcSEcCtD
Gadoversetamide—Hypertension—Doxorubicin—testicular cancer	0.000616	0.000616	CcSEcCtD
Gadoversetamide—Tachycardia—Epirubicin—testicular cancer	0.000614	0.000614	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000613	0.000613	CcSEcCtD
Gadoversetamide—Skin disorder—Epirubicin—testicular cancer	0.000612	0.000612	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Epirubicin—testicular cancer	0.000609	0.000609	CcSEcCtD
Gadoversetamide—Insomnia—Methotrexate—testicular cancer	0.000608	0.000608	CcSEcCtD
Gadoversetamide—Myalgia—Doxorubicin—testicular cancer	0.000608	0.000608	CcSEcCtD
Gadoversetamide—Chest pain—Doxorubicin—testicular cancer	0.000608	0.000608	CcSEcCtD
Gadoversetamide—Arthralgia—Doxorubicin—testicular cancer	0.000608	0.000608	CcSEcCtD
Gadoversetamide—Anxiety—Doxorubicin—testicular cancer	0.000606	0.000606	CcSEcCtD
Gadoversetamide—Paraesthesia—Methotrexate—testicular cancer	0.000604	0.000604	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000603	0.000603	CcSEcCtD
Gadoversetamide—Discomfort—Doxorubicin—testicular cancer	0.0006	0.0006	CcSEcCtD
Gadoversetamide—Anorexia—Epirubicin—testicular cancer	0.0006	0.0006	CcSEcCtD
Gadoversetamide—Dyspnoea—Methotrexate—testicular cancer	0.0006	0.0006	CcSEcCtD
Gadoversetamide—Somnolence—Methotrexate—testicular cancer	0.000598	0.000598	CcSEcCtD
Gadoversetamide—Dry mouth—Doxorubicin—testicular cancer	0.000594	0.000594	CcSEcCtD
Gadoversetamide—Dyspepsia—Methotrexate—testicular cancer	0.000592	0.000592	CcSEcCtD
Gadoversetamide—Hypotension—Epirubicin—testicular cancer	0.000588	0.000588	CcSEcCtD
Gadoversetamide—Confusional state—Doxorubicin—testicular cancer	0.000587	0.000587	CcSEcCtD
Gadoversetamide—Decreased appetite—Methotrexate—testicular cancer	0.000585	0.000585	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Doxorubicin—testicular cancer	0.000583	0.000583	CcSEcCtD
Gadoversetamide—Oedema—Doxorubicin—testicular cancer	0.000583	0.000583	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000581	0.000581	CcSEcCtD
Gadoversetamide—Fatigue—Methotrexate—testicular cancer	0.00058	0.00058	CcSEcCtD
Gadoversetamide—Pain—Methotrexate—testicular cancer	0.000575	0.000575	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000574	0.000574	CcSEcCtD
Gadoversetamide—Shock—Doxorubicin—testicular cancer	0.000573	0.000573	CcSEcCtD
Gadoversetamide—Nervous system disorder—Doxorubicin—testicular cancer	0.000571	0.000571	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Doxorubicin—testicular cancer	0.00057	0.00057	CcSEcCtD
Gadoversetamide—Insomnia—Epirubicin—testicular cancer	0.000569	0.000569	CcSEcCtD
Gadoversetamide—Tachycardia—Doxorubicin—testicular cancer	0.000569	0.000569	CcSEcCtD
Gadoversetamide—Skin disorder—Doxorubicin—testicular cancer	0.000566	0.000566	CcSEcCtD
Gadoversetamide—Paraesthesia—Epirubicin—testicular cancer	0.000565	0.000565	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Doxorubicin—testicular cancer	0.000563	0.000563	CcSEcCtD
Gadoversetamide—Dyspnoea—Epirubicin—testicular cancer	0.000561	0.000561	CcSEcCtD
Gadoversetamide—Somnolence—Epirubicin—testicular cancer	0.00056	0.00056	CcSEcCtD
Gadoversetamide—Anorexia—Doxorubicin—testicular cancer	0.000555	0.000555	CcSEcCtD
Gadoversetamide—Feeling abnormal—Methotrexate—testicular cancer	0.000554	0.000554	CcSEcCtD
Gadoversetamide—Dyspepsia—Epirubicin—testicular cancer	0.000554	0.000554	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Methotrexate—testicular cancer	0.00055	0.00055	CcSEcCtD
Gadoversetamide—Decreased appetite—Epirubicin—testicular cancer	0.000547	0.000547	CcSEcCtD
Gadoversetamide—Hypotension—Doxorubicin—testicular cancer	0.000544	0.000544	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000544	0.000544	CcSEcCtD
Gadoversetamide—Fatigue—Epirubicin—testicular cancer	0.000543	0.000543	CcSEcCtD
Gadoversetamide—Pain—Epirubicin—testicular cancer	0.000538	0.000538	CcSEcCtD
Gadoversetamide—Constipation—Epirubicin—testicular cancer	0.000538	0.000538	CcSEcCtD
Gadoversetamide—Urticaria—Methotrexate—testicular cancer	0.000534	0.000534	CcSEcCtD
Gadoversetamide—Abdominal pain—Methotrexate—testicular cancer	0.000532	0.000532	CcSEcCtD
Gadoversetamide—Body temperature increased—Methotrexate—testicular cancer	0.000532	0.000532	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000531	0.000531	CcSEcCtD
Gadoversetamide—Insomnia—Doxorubicin—testicular cancer	0.000527	0.000527	CcSEcCtD
Gadoversetamide—Paraesthesia—Doxorubicin—testicular cancer	0.000523	0.000523	CcSEcCtD
Gadoversetamide—Dyspnoea—Doxorubicin—testicular cancer	0.000519	0.000519	CcSEcCtD
Gadoversetamide—Feeling abnormal—Epirubicin—testicular cancer	0.000519	0.000519	CcSEcCtD
Gadoversetamide—Somnolence—Doxorubicin—testicular cancer	0.000518	0.000518	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Epirubicin—testicular cancer	0.000515	0.000515	CcSEcCtD
Gadoversetamide—Dyspepsia—Doxorubicin—testicular cancer	0.000513	0.000513	CcSEcCtD
Gadoversetamide—Decreased appetite—Doxorubicin—testicular cancer	0.000506	0.000506	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000503	0.000503	CcSEcCtD
Gadoversetamide—Fatigue—Doxorubicin—testicular cancer	0.000502	0.000502	CcSEcCtD
Gadoversetamide—Urticaria—Epirubicin—testicular cancer	0.0005	0.0005	CcSEcCtD
Gadoversetamide—Pain—Doxorubicin—testicular cancer	0.000498	0.000498	CcSEcCtD
Gadoversetamide—Constipation—Doxorubicin—testicular cancer	0.000498	0.000498	CcSEcCtD
Gadoversetamide—Abdominal pain—Epirubicin—testicular cancer	0.000498	0.000498	CcSEcCtD
Gadoversetamide—Body temperature increased—Epirubicin—testicular cancer	0.000498	0.000498	CcSEcCtD
Gadoversetamide—Hypersensitivity—Methotrexate—testicular cancer	0.000496	0.000496	CcSEcCtD
Gadoversetamide—Asthenia—Methotrexate—testicular cancer	0.000483	0.000483	CcSEcCtD
Gadoversetamide—Feeling abnormal—Doxorubicin—testicular cancer	0.00048	0.00048	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000476	0.000476	CcSEcCtD
Gadoversetamide—Pruritus—Methotrexate—testicular cancer	0.000476	0.000476	CcSEcCtD
Gadoversetamide—Hypersensitivity—Epirubicin—testicular cancer	0.000464	0.000464	CcSEcCtD
Gadoversetamide—Urticaria—Doxorubicin—testicular cancer	0.000463	0.000463	CcSEcCtD
Gadoversetamide—Abdominal pain—Doxorubicin—testicular cancer	0.000461	0.000461	CcSEcCtD
Gadoversetamide—Body temperature increased—Doxorubicin—testicular cancer	0.000461	0.000461	CcSEcCtD
Gadoversetamide—Diarrhoea—Methotrexate—testicular cancer	0.00046	0.00046	CcSEcCtD
Gadoversetamide—Asthenia—Epirubicin—testicular cancer	0.000452	0.000452	CcSEcCtD
Gadoversetamide—Pruritus—Epirubicin—testicular cancer	0.000445	0.000445	CcSEcCtD
Gadoversetamide—Dizziness—Methotrexate—testicular cancer	0.000445	0.000445	CcSEcCtD
Gadoversetamide—Diarrhoea—Epirubicin—testicular cancer	0.000431	0.000431	CcSEcCtD
Gadoversetamide—Hypersensitivity—Doxorubicin—testicular cancer	0.000429	0.000429	CcSEcCtD
Gadoversetamide—Vomiting—Methotrexate—testicular cancer	0.000428	0.000428	CcSEcCtD
Gadoversetamide—Rash—Methotrexate—testicular cancer	0.000424	0.000424	CcSEcCtD
Gadoversetamide—Dermatitis—Methotrexate—testicular cancer	0.000424	0.000424	CcSEcCtD
Gadoversetamide—Headache—Methotrexate—testicular cancer	0.000421	0.000421	CcSEcCtD
Gadoversetamide—Asthenia—Doxorubicin—testicular cancer	0.000418	0.000418	CcSEcCtD
Gadoversetamide—Dizziness—Epirubicin—testicular cancer	0.000416	0.000416	CcSEcCtD
Gadoversetamide—Pruritus—Doxorubicin—testicular cancer	0.000412	0.000412	CcSEcCtD
Gadoversetamide—Vomiting—Epirubicin—testicular cancer	0.0004	0.0004	CcSEcCtD
Gadoversetamide—Nausea—Methotrexate—testicular cancer	0.0004	0.0004	CcSEcCtD
Gadoversetamide—Diarrhoea—Doxorubicin—testicular cancer	0.000399	0.000399	CcSEcCtD
Gadoversetamide—Rash—Epirubicin—testicular cancer	0.000397	0.000397	CcSEcCtD
Gadoversetamide—Dermatitis—Epirubicin—testicular cancer	0.000397	0.000397	CcSEcCtD
Gadoversetamide—Headache—Epirubicin—testicular cancer	0.000394	0.000394	CcSEcCtD
Gadoversetamide—Dizziness—Doxorubicin—testicular cancer	0.000385	0.000385	CcSEcCtD
Gadoversetamide—Nausea—Epirubicin—testicular cancer	0.000374	0.000374	CcSEcCtD
Gadoversetamide—Vomiting—Doxorubicin—testicular cancer	0.00037	0.00037	CcSEcCtD
Gadoversetamide—Rash—Doxorubicin—testicular cancer	0.000367	0.000367	CcSEcCtD
Gadoversetamide—Dermatitis—Doxorubicin—testicular cancer	0.000367	0.000367	CcSEcCtD
Gadoversetamide—Headache—Doxorubicin—testicular cancer	0.000365	0.000365	CcSEcCtD
Gadoversetamide—Nausea—Doxorubicin—testicular cancer	0.000346	0.000346	CcSEcCtD
